<DOC>
	<DOCNO>NCT00518986</DOCNO>
	<brief_summary>The primary objective study evaluate whether armodafinil target dosage 200 mg/day effective placebo treatment improve excessive sleepiness patient obstructive sleep apnea/hypopnea syndrome ( OSAHS ) comorbid major depressive disorder dysthymic disorder .</brief_summary>
	<brief_title>Efficacy Safety Armodafinil Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea Depression</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<mesh_term>Dysthymic Disorder</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Current diagnosis obstructive sleep apnea/hypopnea syndrome ( OSAHS ) Complaint residual excessive sleepiness despite nasal continuous positive airway pressure ( nCPAP ) therapy effective Current prior diagnosis major depressive disorder dysthymic disorder Clinically stable regard depress mood show treatment response selective serotonin reuptake inhibitor ( SSRI ) therapy serotonin norepinephrine reuptake inhibitor ( SNRI ) therapy Patient stable monotherapy dose allow SSRI SNRI least 8 week time screen Women childbearing potential must use medically accept method contraception . Confirmed suspect diagnosis currently active sleep disorder obstructive sleep apnea/hypopnea syndrome ( OSAHS ) Current episode major depression consider treatmentresistant A primary diagnosis : eating disorder , psychotic disorder , delirium , dementia , substancerelated disorder , moderate severe hypochondriasis Patient history bipolar disorder , psychotic depression , schizophrenia , schizoaffective disorder , psychotic disorder , clinically significant uncontrolled psychiatric condition . Patient history homicidal ideation significant aggression Patient diagnosis severe antisocial borderline personality disorder Has history significant suicidal ideation , current active suicidal ideation , consider imminent risk self harm . Patient history consistent fibromyalgia chronic fatigue syndrome A high consumption caffeinated product , approximately equivalent 5 cup coffee per day Patient history clinically significant cutaneous drug reaction , history clinically significant hypersensitivity reaction Has past present seizure disorder Patient history alcohol , narcotic , substance abuse dependence ( exception nicotine ) Psychotherapeutic intervention patient initiate within 8 week screen visit . Patient known human immunodeficiency virus ( HIV ) Patient clinically significant uncontrolled medical condition ( include illness related cardiovascular , renal , hepatic system ) surgical condition ( treat untreated ) Patient pregnant lactate woman Patient previously receive armodafinil ; , patient use modafinil investigational product within 28 day baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Obstructive Sleep Apnea/Hypopnea Syndrome</keyword>
	<keyword>Excessive Sleepiness</keyword>
</DOC>